THIRD QUARTER EARNINGS PRESENTATION NOVEMBER 8, 2022 XXII CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS | --- | |----------------------------------------------------------------------------------------------------| | | | This presentation contains forward-looking statements | | concerning our business operations, and financial performance | | and conditions, as well as our plans, objectives, and | | expectations for our business operations and financial | | performance and conditions that are subject to ris ...

Product Development and Market Expansion - 22nd Century Group, Inc. received FDA Modified Risk Tobacco Product authorization for its VLN® cigarettes, which contain 95% less nicotine than conventional cigarettes [138]. - The company has launched VLN® reduced nicotine cigarettes in over 150 Circle K stores in Chicago and plans to expand to more than 3,000 locations in Colorado [139]. - By the end of 2023, the company aims to launch VLN® in a total of up to 12 to 18 states, having secured regulatory authorizations to sell in 47 states and the District of Columbia [142]. - The company planted its largest VLN® tobacco crop in 2022, achieving 30% higher yields and improved quality, with plans for expansion in 2023 [143]. - The FDA's new leadership is expected to favor policies that support the company's reduced nicotine products, including a proposed nicotine cap in combustible cigarettes [144]. - The company anticipates commercial production of its VLN® 2.0 American blend cigarettes featuring non-GMO reduced nicotine varieties to begin in 2023 [148]. - The global nicotine retail sales were approximately $853 billion in 2021, with 84.1% from combustible cigarettes, indicating a significant market opportunity for VLN® [136]. - The company has provided over 31.6 million variable nicotine research cigarettes for independent clinical studies, with costs exceeding $125 million [134]. - Studies show that smokers using the company's reduced nicotine products reduce nicotine exposure and dependence, smoke fewer cigarettes, and double their quit attempts [135]. Financial Performance - Net revenues for Q3 2022 were $19,383, a 148.2% increase from $7,811 in Q3 2021, driven by contract manufacturing volumes and GVB's full quarter revenue [162]. - Net revenues from tobacco-related products were $11,535, a 47.7% increase from the previous year, while hemp/cannabis-related products generated $7,848 in revenue [162]. - Gross profit for Q3 2022 was $619, reflecting a 112.0% increase from $292 in Q3 2021, despite an inventory write-down of $281 [162]. - Total operating expenses for Q3 2022 rose to $15,887, up from $7,861 in the prior year, primarily due to the GVB acquisition and increased strategic consulting and marketing expenses [162]. - Research and development expenses for Q3 2022 were $1,318, an increase of $287 from the prior year, driven by strategic initiatives and personnel costs [169]. - Sales, general and administrative expenses for Q3 2022 were $14,569, a significant increase of $7,739 from the previous year, largely due to GVB-related expenses and accelerated launch costs for VLN® [171]. Cash Flow and Financial Position - The company had $43,721 in cash, cash equivalents, and short-term investment securities as of September 30, 2022 [162]. - Unrealized loss on investments for Q3 2022 was $(345), a significant improvement from $(1,900) in Q3 2021, indicating better performance in equity securities [175]. - As of September 30, 2022, the company reported an unrealized loss of $345 for the three months and $2,041 for the nine months due to fluctuations in the value of PLSH common stock, which was valued at $299 per share [177]. - Interest expense increased to $(148) for the quarter ended September 30, 2022, compared to $(23) in the same quarter of 2021, primarily due to interest from GVB bridge notes related to the GVB acquisition [178]. - Cash and cash equivalents decreased by $5,015 to $2,364 as of September 30, 2022, primarily due to cash used in operating activities [179]. - Working capital decreased by $222 to approximately $45,736 as of September 30, 2022, primarily due to a $10,238 increase in net current liabilities [180]. - Cash used in operating activities increased by $14,441 to $(32,648) for the nine months ended September 30, 2022, driven by higher SG&A spending [182]. - Cash provided by investing activities decreased by $33,587, primarily due to increased cash used for acquisitions and investments, including GVB and Change Agronomy Ltd. [184]. - Cash provided by financing activities decreased by $18,718, resulting from lower net proceeds from common stock issuances and warrant exercises [185]. - As of September 30, 2022, the company had approximately $43,721 in cash and cash equivalents and short-term investment securities, a decrease of $5,015 from December 31, 2021 [186]. - The company completed a capital raise on July 25, 2022, generating net proceeds of $32,484 to accelerate the launch of VLN® products and meet increased customer demands [188]. - Future cash requirements are anticipated to decrease, reflecting higher sales volume for VLN® products and continued organic growth of GVB's operations [187]. Strategic Acquisitions and Growth - The company is focused on developing proprietary hemp/cannabis varieties for applications in life sciences and consumer products, optimizing plant genetics for high-quality production [149]. - The acquisition of GVB Biopharma is expected to double the company's revenue going forward, enhancing its position in the hemp-derived active ingredients market [154]. - GVB's Prineville facility is one of the largest hemp extraction plants globally, with a projected CBD crude output capacity exceeding 15,000 kg/month at full capacity [155].

X 22ND CENTURY GROUP INVESTOR OVERVIEW October 2022 Nasdaq XXII CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS | --- | |----------------------------------------------------------------------------------------------------| | | | This presentation contains forward-looking statements | | concerning our business operations, and financial performance | | and conditions, as well as our plans, objectives, and | | expectations for our business operations and financial | | performance and conditions that are subject ...

22nd Century Group, Inc. (NASDAQ:XXII) Q2 2022 Earnings Conference Call August 9, 2022 10:00 AM ET Company Participants Joe Schepers - Vice President of Communications & Investor Relations Jim Mish - Chief Executive Officer John Miller - President of Tobacco Business Hugh Kinsman - Chief Financial Officer Conference Call Participants Vivien Azer - Cowen Aaron Grey - Alliance Global Partners Brian Wright - Roth Capital Partners Jim McIlree - Dawson James Alex Berman - Craig-Hallum Capital Group Operator Welc ...

SECOND QUARTER 2022 EARNINGS PRESENTATION August 9, 2022 XXII CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS | --- | |----------------------------------------------------------------------------------------------------| | | | This presentation contains forward-looking statements | | concerning our business operations, and financial performance | | and conditions, as well as our plans, objectives, and | | expectations for our business operations and financial | | performance and conditions that are subject to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ________ to ________ Commission File Number: 001-36338 22nd Century Group, Inc. (Exact name of registrant as specified in its charter) (State or other juri ...

INVESTOR OVERVIEW June 2022 XXII CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS | --- | |-------------------------------------------------------------------| | | | This presentation contains forward-looking statements | | concerning our business operations, and financial performance | | and conditions, as well as our plans, objectives, and | | expectations for our business operations, and financial | | performance, and conditions that are subject to risks and | | uncertainties. All statements other than thos ...

22nd Century Group, Inc. (NASDAQ:XXII) Q1 2022 Earnings Conference Call May 5, 2022 10:00 AM ET Company Participants Mei Kuo – Director of Communications and Investor Relations Jim Mish – Chief Executive Officer Mike Zercher – President and Chief Operating Officer Rich Fitzgerald – Chief Financial Officer Conference Call Participants Harrison Vivas – Cowen Brian Wright – Roth Capital Partners Jim McIlree – Dawson James Operator Welcome to the 22nd Century Group’s First Quarter 2022 Earnings Conference Call. ...

Nasdag XXII 22nd Century Group, Inc. FIRST QUARTER 2022 EARNINGS PRESENTATION May 5, 2022 ELPS YOU HELPS YOU SMOKE LESS LPS YOU MENTHOL 95% LESS NICO Nicotine is addictive. Less nicotine does NOT mean safer. All cigarettes can cause disease and death. Nicotine is addictive. Less nicotine does NOT mean safer. All cigarettes can cause disease and death Nicotine is addictive. Less nicotine does NOT mean safer. All cigarettes can cause disease and death. MENTHOL 95% LESS NICO Nicotine is addictive. Less nicotin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ________ to ________ Commission File Number: 001-36338 22nd Century Group, Inc. (Exact name of registrant as specified in its charter) (State or other jur ...